BriaCell Therapeutics

Beverly Hills, United States Founded: 2004 • Age: 22 yrs
Developer of immunotherapies for the treatment of cancer
Request Access

About BriaCell Therapeutics

BriaCell Therapeutics is a company based in Beverly Hills (United States) founded in 2004.. The company has 18 employees as of July 31, 2024. BriaCell Therapeutics offers products and services including Bria-IMT, Bria-OTS, and Bria-OTS+. BriaCell Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Beverly Hills, United States
  • Employees 18 as on 31 Jul, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Briacell Therapeutics Corp
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0 (USD)
    0
    as on Jul 31, 2024
  • Net Profit
    $-4.52 M (USD)
    76.09
    as on Jul 31, 2024
  • EBITDA
    $-31.41 M (USD)
    -44.81
    as on Jul 31, 2024
  • Latest Funding Round
    $399.92 K (USD), Grant

    Sep 01, 2023

  • Investors
    HHS

    & 4 more

  • Employee Count
    18

    as on Jul 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of BriaCell Therapeutics

BriaCell Therapeutics is a publicly listed company on the TSX with ticker symbol BCT in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TSX · Ticker: BCT . Sector: Health technology · Canada

Products & Services of BriaCell Therapeutics

BriaCell Therapeutics offers a comprehensive portfolio of products and services, including Bria-IMT, Bria-OTS, and Bria-OTS+. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets metastatic breast cancer through immune activation in clinical trials.

Provides off-the-shelf personalized treatment for breast and prostate cancers.

Enhanced version for various cancers, including prostate, via HLA matching.

People of BriaCell Therapeutics
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 12
Employee Profiles
People
Miguel A. Lopez-Lago
Senior Director of Research & Development
People
William V. Williams
President & CEO
People
Pravin Kesarwani
Principal Scientist
People
Xiaoyi Zheng
Scientist

Unlock access to complete

Board Members and Advisors
people
Jane A. Gross
Director
people
Jamieson Bondarenko
Chairman
people
Martin E. Schmieg
Director
people
Rebecca Taub
Director

Unlock access to complete

Funding Insights of BriaCell Therapeutics

  • Total Funding
  • Total Rounds 18
  • Last Round Grant — $399,918
  • First Round

    (23 May 2014)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2023 Amount Grant - BriaCell Therapeutics Valuation

investors

HHS
Aug, 2023 Amount Grant - BriaCell Therapeutics Valuation

investors

May, 2023 Amount Post-IPO - BriaCell Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BriaCell Therapeutics

BriaCell Therapeutics has secured backing from 5 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, National Cancer Institute and Prevail Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Limited information is provided about Prevail Partners' activities.
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Cancer research is conducted and supported by the institute.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BriaCell Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - BriaCell Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Briacell Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BriaCell Therapeutics

BriaCell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Briacell Therapeutics

Frequently Asked Questions about BriaCell Therapeutics

When was BriaCell Therapeutics founded?

BriaCell Therapeutics was founded in 2004 and raised its 1st funding round 10 years after it was founded.

Where is BriaCell Therapeutics located?

BriaCell Therapeutics is headquartered in Beverly Hills, United States. It is registered at Beverly Hills, California, United States.

How many employees does BriaCell Therapeutics have?

As of Jul 31, 2024, the latest employee count at BriaCell Therapeutics is 18.

What does BriaCell Therapeutics do?

Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.

Who are the top competitors of BriaCell Therapeutics?

BriaCell Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does BriaCell Therapeutics offer?

BriaCell Therapeutics offers Bria-IMT, Bria-OTS, and Bria-OTS+.

Is BriaCell Therapeutics publicly traded?

Yes, BriaCell Therapeutics is publicly traded on TSX under the ticker symbol BCT.

Who are BriaCell Therapeutics's investors?

BriaCell Therapeutics has 5 investors. Key investors include HHS, National Cancer Institute, Prevail Partners, Wiseman Cancer Research Foundation, and Jamieson Bondarenko.

What is BriaCell Therapeutics's ticker symbol?

The ticker symbol of BriaCell Therapeutics is BCT on TSX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available